Kyverna Therapeutics (KYTX) Competitors $2.36 -0.14 (-5.60%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$2.49 +0.13 (+5.51%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. PRTC, SLDB, GLUE, ERAS, MREO, SNDL, TRDA, SIGA, ETON, and KMDAShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include PureTech Health (PRTC), Solid Biosciences (SLDB), Monte Rosa Therapeutics (GLUE), Erasca (ERAS), Mereo BioPharma Group (MREO), SNDL (SNDL), Entrada Therapeutics (TRDA), SIGA Technologies (SIGA), Eton Pharmaceuticals (ETON), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. PureTech Health Solid Biosciences Monte Rosa Therapeutics Erasca Mereo BioPharma Group SNDL Entrada Therapeutics SIGA Technologies Eton Pharmaceuticals Kamada Kyverna Therapeutics (NASDAQ:KYTX) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings. Which has better earnings and valuation, KYTX or PRTC? Kyverna Therapeutics has higher revenue and earnings than PureTech Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M14.49-$60.37MN/AN/APureTech Health$3.33M135.17-$65.70MN/AN/A Does the media prefer KYTX or PRTC? In the previous week, Kyverna Therapeutics had 3 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Kyverna Therapeutics and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.93 beat Kyverna Therapeutics' score of -0.06 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate KYTX or PRTC? Kyverna Therapeutics presently has a consensus target price of $18.40, indicating a potential upside of 679.66%. PureTech Health has a consensus target price of $45.00, indicating a potential upside of 140.13%. Given Kyverna Therapeutics' higher possible upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than PureTech Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is KYTX or PRTC more profitable? PureTech Health's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% PureTech Health N/A N/A N/A Does the MarketBeat Community believe in KYTX or PRTC? Kyverna Therapeutics received 1 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 66.67% of users gave Kyverna Therapeutics an outperform vote while only 45.00% of users gave PureTech Health an outperform vote. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1066.67% Underperform Votes533.33% PureTech HealthOutperform Votes945.00% Underperform Votes1155.00% Do insiders and institutionals hold more shares of KYTX or PRTC? 18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryKyverna Therapeutics beats PureTech Health on 8 of the 14 factors compared between the two stocks. Remove Ads Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.89M$3.04B$5.65B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E RatioN/A29.2923.1419.03Price / Sales14.49436.17385.7893.17Price / CashN/A168.6838.1634.64Price / BookN/A3.956.934.33Net Income-$60.37M-$71.95M$3.20B$247.06M7 Day Performance-0.84%-3.76%-2.30%-0.37%1 Month Performance-16.90%-10.33%2.86%-3.85%1 Year Performance-90.50%-27.15%10.66%1.27% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics1.4557 of 5 stars$2.36-5.6%$18.40+679.7%-90.2%$101.89M$7.03M0.0096Earnings ReportNews CoverageGap UpPRTCPureTech Health1.5493 of 5 stars$17.99+3.1%$45.00+150.2%-34.6%$430.65M$3.33M0.00100Gap DownSLDBSolid Biosciences3.4274 of 5 stars$5.36+5.3%$15.67+192.3%-69.3%$415.36M$8.09M-1.76100Positive NewsGLUEMonte Rosa Therapeutics2.9993 of 5 stars$6.73+7.3%$15.25+126.6%-25.3%$413.47M$14.98M-3.6890Short Interest ↓ERASErasca3.6638 of 5 stars$1.46+1.4%$4.90+235.6%-24.8%$412.78MN/A-1.76120Analyst ForecastNews CoverageMREOMereo BioPharma Group2.2394 of 5 stars$2.63+0.4%$7.83+197.8%-19.7%$408.03M$1M0.0040Earnings ReportAnalyst ForecastNews CoveragePositive NewsSNDLSNDL3.6135 of 5 stars$1.55+2.6%$3.25+109.7%-31.2%$407.30M$911.22M-5.002,516TRDAEntrada Therapeutics3.0216 of 5 stars$10.81flat$25.67+137.4%-30.6%$406.40M$210.78M6.80110SIGASIGA Technologies2.5817 of 5 stars$5.63+0.9%N/A-34.5%$402.19M$138.72M4.6940Positive NewsETONEton Pharmaceuticals2.783 of 5 stars$15.29-1.9%$24.00+57.0%+255.5%$398.32M$34.68M-69.5020Short Interest ↓KMDAKamada3.5911 of 5 stars$6.80-5.3%$14.50+113.2%+22.0%$390.86M$160.95M24.29360Analyst DowngradeShort Interest ↑High Trading Volume Remove Ads Related Companies and Tools Related Companies PRTC Alternatives SLDB Alternatives GLUE Alternatives ERAS Alternatives MREO Alternatives SNDL Alternatives TRDA Alternatives SIGA Alternatives ETON Alternatives KMDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYTX Stock Free KYTX Stock Alerts